WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522402
Description: MDL-105519 is a high affinity NMDA glutamate receptor antagonist at the glycine site. MDL 105,519 prevented harmaline-stimulated increases in cerebellar cyclic GMP content, providing biochemical evidence of NMDA receptor antagonism in vivo. This antagonism was associated with anticonvulsant activity in genetically based, chemically induced, and electrically mediated seizure models.
MedKoo Cat#: 522402
Chemical Formula: C18H11Cl2NO4
Exact Mass: 375.00651
Molecular Weight: 376.18
Elemental Analysis: C, 57.47; H, 2.95; Cl, 18.85; N, 3.72; O, 17.01
MDL-105519 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: MDL-105519; MDL 105519; MDL105519; MDL105,519; MDL-105,519; MDL 105,519
IUPAC/Chemical Name: (E)-3-(2-carboxy-2-phenylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acid
InChi Key: LPWVUDLZUVBQGP-DHZHZOJOSA-N
InChi Code: InChI=1S/C18H11Cl2NO4/c19-10-6-13(20)15-12(16(18(24)25)21-14(15)7-10)8-11(17(22)23)9-4-2-1-3-5-9/h1-8,21H,(H,22,23)(H,24,25)/b11-8+
SMILES Code: ClC1=C2C(NC(C(O)=O)=C2/C=C(C3=CC=CC=C3)/C(O)=O)=CC(Cl)=C1
The following data is based on the product molecular weight 376.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Kakuda T, Nozawa A, Sugimoto A, Niino H. Inhibition by theanine of binding of [3H]AMPA, [3H]kainate, and [3H]MDL 105,519 to glutamate receptors. Biosci Biotechnol Biochem. 2002 Dec;66(12):2683-6. PubMed PMID: 12596867.
2: Sharma TA, Reynolds IJ. Complex polyamine effects on [3H]MDL 105,519 binding to the NMDA receptor glycine site. Neurochem Int. 1998 Aug;33(2):155-9. PubMed PMID: 9761459.
3: Chazot PL, Reiss C, Chopra B, Stephenson FA. [3H]MDL 105,519 binds with equal high affinity to both assembled and unassembled NR1 subunits of the NMDA receptor. Eur J Pharmacol. 1998 Jul 17;353(1):137-40. PubMed PMID: 9721050.
4: Höfner G, Wanner KT. Characterisation of the binding of [3H]MDL 105,519, a radiolabelled antagonist for the N-methyl-D-aspartate-associated glycine site, to pig cortical brain membranes. Neurosci Lett. 1997 Apr 25;226(2):79-82. PubMed PMID: 9159494.
5: Baron BM, Harrison BL, Kehne JH, Schmidt CJ, van Giersbergen PL, White HS, Siegel BW, Senyah Y, McCloskey TC, Fadayel GM, Taylor VL, Murawsky MK, Nyce P, Salituro FG. Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist. Eur J Pharmacol. 1997 Apr 4;323(2-3):181-92. PubMed PMID: 9128837.
6: Siegel BW, Sreekrishna K, Baron BM. Binding of the radiolabeled glycine site antagonist [3H]MDL 105,519 to homomeric NMDA-NR1a receptors. Eur J Pharmacol. 1996 Oct 3;312(3):357-65. PubMed PMID: 8894619.
7: Baron BM, Siegel BW, Harrison BL, Gross RS, Hawes C, Towers P. [3H]MDL 105,519, a high-affinity radioligand for the N-methyl-D-aspartate receptor-associated glycine recognition site. J Pharmacol Exp Ther. 1996 Oct;279(1):62-8. PubMed PMID: 8858976.